Engineered Lipopeptides Deliver Gene-Silencing RNA Into Aggressive Breast Cancer Cells

The researchers designed peptide transporters using computational studies and molecular dynamics simulations to optimize the Arg-DHis-Arg template. They synthesized cyclic and linear lipopeptide variants with different lipid modifications (including linoleic acid). They tested siRNA delivery, gene silencing (ERK1/2 knockdown), serum stability, and protease resistance in TNBC cell lines. Combination therapy experiments paired siRNA delivery with doxorubicin.

Triple-negative breast cancer is the most aggressive breast cancer subtype with limited targeted treatment options. RNA-based therapies could specifically silence cancer-driving genes, but delivering fragile siRNA molecules into cells has been a major bottleneck. These engineered lipopeptides solve multiple delivery challenges — membrane penetration, endosomal escape, and serum stability — in one designed molecule.

RNA-based therapeutics are a rapidly growing field following the success of mRNA vaccines and FDA-approved siRNA drugs. Peptide-based delivery systems are attractive because they can be rationally designed, are biodegradable, and can be tuned for specific cell types. This work advances the design principles for pH-responsive peptide carriers that could enable the next generation of targeted RNA therapies for difficult-to-treat cancers.

All experiments were conducted in cell culture, not in animal models or patients. The comparison was made to a commercial transfection reagent, not to clinically relevant delivery systems. Toxicity profiles in normal cells and in vivo biodistribution were not reported. The scalability of lipopeptide synthesis for clinical use was not addressed.